Net Asset Value(s)

RNS Number : 8105Q

Port Erin Biopharma Investments Ltd

18 October 2013

 



Port Erin Biopharma Investments Limited

 (the "Company")

Net Asset Value calculation to 30 September 2013

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 30 September 2013 was 17.13 pence per share, including un-invested cash of £742,497 and an accrual of £353,041 for the management fee. The portfolio is valued under IFRS at bid price. This quarter's asset value before management fee represents an increase of 70.9% from the previous valuation of 10.63 pence per share, which included un-invested cash of £707,624. This excellent performance represents increase of 128% over the cash available for investment at inception after listing and operating costs."

		Unaudited to 30 September 2013 £
Fixed Assets
	Investments	5,434,074
Current Assets
	Debtors: amounts owing	9,219
	Un-invested cash	742,497
Current Liabilities
	Creditors: amounts due	(32,049)
		6,153,741
Capital and Reserves
	Share Capital	34
	Share Premium	2,759,551
	Current year's earnings	2,553,790
	Retained earnings	840,366
		6,153,741
Shares in Issue		33,864,836
Asset Value per share pre management fee		18.17 pence
Management fee accrual		353,041
Net Asset Value per share		17.13 pence

--- ENDS ---

Portfolio Details

Investments as at 30 September 2013	Value	% of Total Portfolio
Summit Corporation plc	£1,341,666	24.7%
Plethora Solutions Holdings plc	£968,749	17.8%
Arrowhead Research	£562,557	10.4%
Synergy Pharmaceuticals Inc.	£276,949	5.1%
Ampliphi Biosciences Corp.	£207,319	3.8%
	£3,357,243	61.8%
Aggregate value of remaining holdings below 3% of total portfolio	£2,076,834	38.2%
TOTAL INVESTMENTS	£5,434,074	100.0%

For further information, please contact:

Port Erin Biopharma Investments Ltd	Libertas Capital Corporate Finance Limited	Peterhouse Capital Limited
The Company	Nomad	Broker
Denham Eke [phone]	Sandy Jamieson [phone]	Jon Levinson [phone]

 

END

 

 

NAVMMMMGNNFGFZM